论文部分内容阅读
生物技术风险投资业内人士认为,在生物技术领域,中国与世界的距离要小得多,甚至有所领先,表示将向生物医药大力倾斜。据介绍,美国1300家生物技术公司中,10%左右通过自增发展,其余大部通过吸收风险投资基金和股票上市进行融资。每年融资额增长20%,销售额增长20%,就业率增长12.5%,股值增长8.76%。而且目前国内有各类风险投资机构92家,资产74亿元。中国也应开通风险投资多渠道(包括民间的),加大对生物技术开发投入。风险投资业内人士认为,生物医药产业是一项高利润高回报的产业,它的利润率达到了17.6%,是信息产业8.1%的两倍,也远高于7%的计算机。因此应当建立高技术风险投资基金,刺激生物技术产业的发展。据报道,中国有200多家现代生物技术企业,1998年生物技术产品销售额115亿元人民币。
Biotechnology venture capital industry believes that in the field of biotechnology, China is much smaller than the world or even ahead of the world, said it would strongly biomedical tilt. According to reports, the United States 1,300 biotechnology companies, about 10% through self-development, most of the other through the absorption of venture capital funds and stock market financing. Annual financing increased by 20%, sales increased by 20%, the employment rate increased by 12.5%, the stock value increased by 8.76%. And currently there are 92 types of venture capital institutions in China, with assets of 7.4 billion yuan. China should also launch multi-channel venture capital (including private sector) and increase investment in biotechnology development. Venture capital industry believes that the biomedical industry is a high profit and high return of the industry, its profit margin reached 17.6%, 8.1% of the information industry twice, but also much higher than 7% of the computers. Therefore, high-tech venture capital funds should be set up to stimulate the development of the biotechnology industry. It is reported that China has more than 200 modern biotechnology companies, biotech products in 1998 sales of 11.5 billion yuan.